BG
SRNE

BlackRock Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

BlackRock Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$37K Buy
+7,477
New +$44.9K ﹤0.01% 2935
2014
Q2 		– Sell
-17,439
Closed -$223K – 2882
2014
Q1 		$223K Buy
+17,439
New +$193K ﹤0.01% 2448

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock Group's SRNE Position: Q4 2016 in Review

BlackRock Group opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q4 2016: 7,477 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #2935 among its holdings. This is a return to the name: BlackRock Group previously reported a position in SRNE as recently as Q1 2014.

BlackRock Group first reported a position in SRNE in Q1 2014 and has held it in 2 quarters since. The position peaked at $223K in Q1 2014. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

  • BlackRock Group held 7,477 shares of Sorrento Therapeutics, Inc. worth $37K as of Q4 2016.
  • Sorrento Therapeutics, Inc. was a new BlackRock Group position in Q4 2016.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2935 holding.
  • BlackRock Group first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and has held it in 2 quarters since.
  • BlackRock Group's Sorrento Therapeutics, Inc. position peaked at $223K in Q1 2014.
  • 68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.